Phosphodiesterase inhibitors, such as apremilast, are newer drugs that have been shown in studies to be useful in the treatment of some patients with psoriasis, but are not yet widely used in the clinic and lack sufficient clinical evidence to support them. 1. Inhibitors of phosphodiesterase-4, such as apremilast, are newer drugs that antagonize inflammatory factors. Studies have shown that it can be used in adults with active psoriatic arthritis as well as moderate-to-severe plaque psoriasis, and that long-term use may have a role in improving the condition of the patient’s lesions. 2. Because this product has not been widely used in clinical practice, there is a lack of sufficient clinical evidence to support its specific side effects and adverse reactions are not yet known, and further clinical observation and in-depth research are needed. If psoriasis patients have the need to use it, it is recommended to choose the appropriate medication according to the patient’s condition under the guidance of a doctor, and do not use the medication on your own.